Amlexanox and UPF1 modulate Wnt signaling and apoptosis in HCT-116 colorectal cancer cells

Journal of Cancer

Volumn 10, Issue 2, 2019, Pages 287-292

  Bordonaro, Michael ^a   Lazarova, Darina ^a  

^a Janet Weis Children s Hospital   (United States)

Author keywords

Amlexanox; Butyrate; Colorectal cancer; Nonsense mediated decay; Premature termination codon; Wnt signaling

Indexed keywords

AMLEXANOX; ATALUREN; BUTYRIC ACID; CASPASE 3; CASPASE 7; HEMOGLOBIN BETA CHAIN; NUCLEIC ACID BINDING PROTEIN; UNCLASSIFIED DRUG; UP FRAMESHIFT PROTEIN 1; WNT PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DIETARY FIBER; HCT 116 CELL LINE; HUMAN; HUMAN CELL; HUMAN EMBRYONIC STEM CELL; MAXIMUM PLASMA CONCENTRATION; MICROSATELLITE INSTABILITY; NONSENSE MEDIATED MRNA DECAY; PROTEIN EXPRESSION; STOP CODON; TRANSCRIPTION TERMINATION; WNT SIGNALING;

EID: 85059594421     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.28331     Document Type: Article

References (34)

1. Metze S, Herzog VA, Ruepp MD, et al. Comparison of EJC-enhanced and EJC-independent NMD in human cells reveals two partially redundant degradation pathways. RNA. 2013; 19:1432-48.
2. Hug N, Longman D, Cáceres JF. Mechanism and regulation of the nonsense-mediated decay pathway. Nucleic Acids Res. 2016; 44:1483-95.
3. Popp MW, Maquat LE. Leveraging Rules of Nonsense-Mediated mRNA Decay for Genome Engineering and Personalized Medicine. Cell. 2016; 165:1319-22.
4. Nickless A, Bailis JM, You Z. Control of gene expression through the nonsense -mediated RNA decay pathway. Cell Biosci. 2017; 7:26
5. Wengrod J, Martin L, Wang D, et al. Inhibition of nonsense-mediated RNA decay activates autophagy. Mol Cell Bio. 2013; 33: 2128-35.
6. El-Bchiri J, Guilloux A, Dartigues P, et al. Nonsense-mediated mRNA decay impacts MSI-driven carcinogenesis and anti-tumor immunity in colorectal cancers. PLoS One. 2008; 3:e2583.
7. Lindeboom RGH, Supek F, Lehner B. The rules and impact of nonsense-mediated decay in human cancers. Nat Genet. 2016; 48:112-8.
8. Wang D, Zavadi Jl, Martin L, et al. Inhibition of nonsense-mediated RNA decay by the tumor microenvironment promotes tumorigenesis. Mol Cell Bio. 2011; 31:3670-80.
9. Bingham SA, Day NE, Luben R, et al. Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition [EPIC]: an observational study. Lancet. 2003; 361:1496-501.
10. Bordonaro M, Lazarova D, Sartorelli AC. Hyperinduction of WNT signaling: a new paradigm for the treatment of colorectal cancer? Oncol Res. 2008; 17:1-9.
11. Bordonaro M, Lazarova DL, Sartorelli AC. The activation of beta-catenin by WNT signaling mediates the effects of histone deacetylase inhibitors. Exp Cell Res. 2007; 313:1652-66.
12. Chiaro C, Lazarova DL, Bordonaro M. Tcf3 and cell cycle factors contribute to butyrate resistance in colorectal cancer cells. Biochem Biophys Res Commun. 2012; 428:121-6.
13. Lazarova DL, Chiaro C, Wong T, et al. CBP activity mediates effects of the histone deacetylase inhibitor butyrate on Wnt activity and apoptosis in colon cancer cells. J Cancer. 2013; 4:481-90.
14. Lazarova DL, Wong T, Chiaro C, et al. p300 influences butyrate-mediated WNT hyperactivation in colorectal cancer cells. J Cancer. 2013; 4:491-501.
15. Lazarova D, Lee A, Wong T, et al. Modulation of Wnt Activity and cell physiology by butyrate in LT97 microadenoma cells. J Cancer. 2014; 5:203-13.
16. Lazarova DL, Chiaro C, Bordonaro M. Butyrate induced changes in Wnt-signaling specific gene expression in colorectal cancer cells. BMC Research Notes. 2014; 7:226.
17. Lazarova DL, Bordonaro M. Extreme fluctuations in Wnt/beta-catenin signaling as an approach for colon cancer prevention and therapy. Advanced Studies in Biology. 2012; 4:351-62.
18. Lazarova DL, Bordonaro M. p300 knockout promotes butyrate resistance. J Cancer. 2017; 8:3405-9.
19. Lou CH, Dumdie J, Goetz A, et al. Nonsense-mediated RNA decay influences human embryonic stem cell fate. Stem Cell Reports. 2016; 6:844-57.
20. Boelz S, Neu-Yilik G, Gehring NH, et al. A chemiluminescence-based reporter system to monitor nonsense-mediated mRNA decay Biochemical and Biophysical Research Communications. 2006; 349:186-91.
21. Gonzalez-Hilarion S, Beghyn T, Jia J, et al. Rescue of nonsense mutations by Amlexanox in human cells. Orphanet J Rare Dis. 2012; 7:58.
22. Peltz SW, Morsy M, Welch EM, et al. Ataluren as an agent for therapeutic nonsense suppression. Annu Rev Med. 2013; 64:407-25.
23. Roy B, Friesen WJ, Tomizawa Y, et al. Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression. Proc Natl Acad Sci. 2016; 11312508-13.
24. Siddiqui N, Sonenberg N. Proposing a mechanism of action for ataluren. Proc Natl Acad Sci U S A. 2016; 113:12353-5.
25. Bolze F, Mocek S, Zimmerman A, et al. Aminoglycosides, but not PTC124 (Ataluren), rescue nonsense mutations in the leptin receptor and in luciferase reporter genes. Sci Rep. 2017; 7:1020.
26. Krubasik D, Iyer NG, English WR, et al. Absence of p300 induces cellular phenotype changes characteristic of epithelial to mesenchyme transition. Br J Cancer. 2006; 94:1326-32.
27. Ionov Y, Matsui S-I, Cowell JK. A role for p300/CREB binding protein genes in promoting cancer progression in colon cancer cell lines with microsatellite instability. Proc Natl Acad Sci USA. 2004; 101:1273-8.
28. Martincorena I, Campbell PJ. Somatic mutation in cancer and normal cells. Science. 2015; 349:1483-8.
29. Iyer NG, Ozdag H, Caldas C. p300/CBP and cancer. Oncogene. 2004; 23:4225-31.
30. Peccarelli M, Kebaara B. Regulation of natural mRNAs by the nonsense-mediated mRNA decay pathway. Euk Cell. 2014; 13: 1126-35.
31. Martin L, Grigoryan A, Wang D, et al. Identification and characterization of small molecules that inhibit nonsense mediated RNA decay and suppress nonsense p53 mutations. Cancer Res. 2014;74: 3104-13.
32. Bell J. Amlexanox for the treatment of recurrent aphthous ulcers. Clin Drug Investig. 2005; 25:555-66.
33. Hsu C-W, Shou D, Huang R, et al. Identification of HDAC inhibitors using a cell-based HDACI/II assay. J Biomol Screen. 2016; 21: 643-52.
34. Goentoro L, Kirschner MW. Evidence that fold-change, and not absolute level, of beta-catenin dictates Wnt signaling. Mol Cell. 2009; 36:872-84.